The Kali Drop device was used to measure adherence to using corticosteroid drops following glaucoma surgery and to compare adherence rates with target IOP outcomes.

This chart review identified patients with glaucoma or ocular surface disease who were fitted with a Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device and how those with glaucoma responded.

Recommendations distilled from the PPPs for the diagnosis and management of primary open-angle glaucoma, primary open-angle glaucoma suspect, and primary angle-closure disease

Weekly case challenge

Weekly case challenge

Dr. Janet Serle discusses the newest IOP-lowering glaucoma medications, including latanoprostene bunod or LBN, netarsudil, fixed-dose combination netarsudil/latanoprost, and the bimatoprost implant.

In this video, Dr. Angelo Tanna discusses what medication to add for a patient who needs a second medication to control intraocular pressure (IOP). He shares findings from a meta-analysis of randomized clinical trials assessing the IOP-lowering efficacy of alpha 2 adrenergic agonists, beta blockers, and carbonic anhydrase inhibitors, when added to a prostaglandin analog.

In this presentation from the AGS 2020, Dr. Ensign discusses sustained release methods to delivery ophthalmic drugs. She highlights developments in intraocular injections, sustained drug release and the use of prostaglandin.

This study assessed visual field outcomes in patients undergoing selective laser trabeculoplasty (SLT) versus medical therapy as a first-line treatment for ocular hypertension and glaucoma.